Search

Displaying results 401 - 410 of 10000 in total
  1. Drug

    Clonazepam

    go.drugbank.com/drugs/DB01068
    ApprovedIllicitInvestigational

    [FDA Label][A175438,A175441,L5572,F3763,F3787,F3796] Since being first patented in 1960 and then released for sale from Roche in the US in 1975,[T469,T472] clonazepam has experienced a storied history … in the treatment of the aforementioned medical conditions.

    Synonyms: 5-(2-chlorophenyl)-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one, 5-(2-chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-oneProducts: RIVOTRIL ® TABLETAS DE 2.0 MG., CLONAZEPAM EG
  2. Drug

    Tilmicosin

    go.drugbank.com/drugs/DB11471
    InvestigationalVet approved

    It is used in veterinary medicine for the treatment of bovine respiratory disease and ovine respiratory disease associated with _Mannheimia haemolytica_.

    Products: JinPlus 250 mg/ml Oral Liquid, VMT 250 mg/ml Oral Solution
  3. Drug

    Larotrectinib

    go.drugbank.com/drugs/DB14723
    ApprovedInvestigational

    an important role in tumor cell growth and survival. … of cell growth in tumors that overexpress Trk.

    Products: VITRAKVI 20 MG/ML ORAL ÇÖZELTİ, 2x50 ML, VITRAKVI 100 MG SERT KAPSÜL, 56 ADET
  4. Drug

    Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen

    go.drugbank.com/drugs/DB14394
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Synonyms: Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen, Influenza a Virus A/california/7/2009 (H1n1) Live(attenuated) AntigenProducts: Influenza A H1N1 2009 Monovalent Vaccine Live Intranasal
  5. Drug

    Certolizumab pegol

    go.drugbank.com/drugs/DB08904
    ApprovedInvestigational

    [A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819] … [A176585] It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region.

    Products: CIMZIA 200 MG ILO IN FER, CIMZIA 200 MG
  6. Drug

    Flavoxate

    go.drugbank.com/drugs/DB01148
    Approved

    A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. … It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem]

    Products: URISPAS 200 TABLET 200 mg, FLOVOX® 200 MG
  7. Drug

    Flucloxacillin

    go.drugbank.com/drugs/DB00301
    ApprovedInvestigationalWithdrawn

    Antibiotic analog of cloxacillin.

    Products: Flucloxacillin Kabi 2000 mg Pulver zur Herstellung einer Injektions-/Infusionslösung, Flucloxacillin Noridem 2000 mg Pulver zur Herstellung einer Injektions-/Infusionslösung
  8. Drug

    Lapatinib

    go.drugbank.com/drugs/DB01259
    ApprovedInvestigational

    It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. … Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer.

    Synonyms: N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamineProducts: TYKERB 250 MG FILM TABLET, 70 ADET, LAPATINIB EG
  9. Drug

    Hydrogenated soybean oil

    go.drugbank.com/drugs/DB11302
    Approved

    Linolenic acid and stearic acids are contained in hydrogenated soybean oil, but hydrogenation results in reduced unsaturation in linolenic acid. … It may be found in cosmetics and personal care products as an emollient or skin conditioning agent.

    Products: S Balloon Slim Body Line
  10. Drug

    Linagliptin

    go.drugbank.com/drugs/DB08882
    ApprovedInvestigational

    Linagliptin was approved by the FDA on May 2, 2011[L9557]. … Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding[A37050

    Mixtures: TRAYENTA® DUO 2.5 MG/500MG, ทราเจนต้า ดูโอ 2.5/500 มก.Categories: Drugs Used in Diabetes